Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-03-2009 | Retinal Disorders

Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization

Authors: Lazaros Konstantinidis, Irmela Mantel, Jean-Antoine C. Pournaras, Leonidas Zografos, Aude Ambresin

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 3/2009

Abstract

Background

Macular choroidal neovascularization (CNV) is one of the most vision-threatening complications of myopia, which can lead to severe vision loss. The purpose of this study was to evaluate the safety and efficacy of intravitreal ranibizumab in the treatment of myopic CNV.

Methods

We conducted a prospective, consecutive, interventional study of patients with subfoveal or juxtafoveal CNV secondary to pathologic myopia (PM) treated with intravitreal injection of ranibizumab in the Jules Gonin University Eye Hospital from June 2006 to February 2008. Best-corrected visual acuity (BCVA), optical coherence tomography (OCT), and fluorescein angiography (FA) were performed at baseline and monthly for all patients. Indications for retreatment were loss in BCVA associated either with persistent leakage from CNV shown on FA, and/or evidence of CNV activity on OCT.

Results

The study included 14 eyes of 14 patients. The mean spherical equivalent refractive error was −12.5 (range, −8.0 D to −16.0 D). Mean time of follow-up was 8.4 months (range from 3 to 16 months, SD: 3). The mean number of intravitreal injections administered for each patient was 2.36 (SD 1.5). The mean initial visual acuity (VA) was 0.19 decimal equivalent (logMAR: 0.71, SD: 0.3). A statistically significant improvement to a mean VA of 0.48 decimal equivalent (log-MAR:0.32, SD: 0.25) was demonstrated at the final follow-up. VA improved by a mean of 3.86 (SD 2.74) lines. Nine patients (64%) demonstrated a gain of 3 or more lines. Mean central macular thickness (CMT) measured with OCT was 304 μm (SD: 39) at the baseline, and was reduced significantly at the final follow-up to 153 μm (SD: 23). Average CMT reduction was 170 μm (SD: 57). No injection complications or drug-related side effects were noted during the follow-up period.

Conclusions

In this small series of eyes with limited follow-up, intravitreal ranibizumab was a safe and effective treatment for CNV secondary to PM, resulting in functional and anatomic improvements.

Hampton GR, Kohen D, Bird AC (1983) Visual prognosis of disciform degeneration in myopia. Ophthalmology 90:923–926PubMed

Miller DG, Singerman LJ (2001) Natural history of choroidal neovascularization in high myopia. Curr Opin Ophthalmol 12:222–224. doi:10.1097/00055735-200106000-00014 PubMedCrossRef

Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL (1984) Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91:1573–1581PubMed

Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241–1244PubMed

Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial–VIP report no. 3. Ophthalmology 110:667–673. doi:10.1016/S0161-6420(02)01998-X PubMedCrossRef

Secretan M, Kuhn D, Soubrane G, Coscas G (1997) Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 7:307–316PubMed

Mateo C, Moreno J, Rosales G, Lechuga M, Castillo R, Vaz F, Corcostegui B (2004) Two-year results of macular translocation with scleral infolding in myopic choroidal neovascularisation. Semin Ophthalmol 19:29–42. doi:10.1080/08820530490520013 PubMedCrossRef

Fujii GY, Humayun MS, Pieramici DJ, Schachat AP, Au Eong KG, de Juan E Jr (2001) Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration. Am J Ophthalmol 131:90–100. doi:10.1016/S0002-9394(00)00769-8 PubMedCrossRef

Ruiz-Moreno JM, de la Vega C (2001) Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 85:1041–1043. doi:10.1136/bjo.85.9.1041 PubMedCrossRef

10.

Kobayashi H, Kobayashi K (2000) Radiotherapy for subfoveal neovascularisation associated with pathological myopia: a pilot study. Br J Ophthalmol 84:761–766. doi:10.1136/bjo.84.7.761 PubMedCrossRef

11.

Liu DT, Lam DS, Chan WM (2004) Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of ingrowth site treatment. Am J Ophthalmol 137:383 author reply 383-386. doi:10.1016/j.ajo.2003.10.015 PubMedCrossRef

12.

Costa RA, Calucci D, Teixeira LF, Cardillo JA, Bonomo PP (2003) Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of ingrowth site treatment. Am J Ophthalmol 135:857–866. doi:10.1016/S0002-9394(02)02257-2 PubMedCrossRef

13.

Montero JA, Ruiz-Moreno JM (2007) Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 91:131–133. doi:10.1136/bjo.2006.106526 PubMedCrossRef

14.

Chan WM, Lai TY, Wong AL, Liu DT, Lam DS (2007) Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 91:174–179. doi:10.1136/bjo.2006.103606 PubMedCrossRef

15.

Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, Nguyen L, Foidart JM, Noel A, Munaut C (2003) Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3186–3193. doi:10.1167/iovs.02-1092 PubMedCrossRef

16.

Otani A, Takagi H, Oh H, Koyama S, Ogura Y, Matumura M, Honda Y (2002) Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 64:162–169. doi:10.1006/mvre.2002.2407 PubMedCrossRef

17.

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431. doi:10.1056/NEJMoa054481 PubMedCrossRef

18.

Chan WM, Lai TY, Liu DT, Lam DS (2007) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 114(12):2190–2196. doi:10.1016/j.ophtha.2007.03.043 PubMedCrossRef

19.

Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, Fromow-Guerra J, Amaya-Espinosa A, Solis-Vivanco A, Reyna-Castelan E, Abraham-Marin M, Martinez-Castellanos MA, Aiello LP (2007) Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 27:707–712PubMed

20.

Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr (2006) Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26:960–963. doi:10.1097/01.iae.0000240121.28034.c3 PubMedCrossRef

21.

Mandal S, Venkatesh P, Sampangi R, Garg S (2007) Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 17:620–626PubMed

22.

Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA (2005) Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89:1368–1370. doi:10.1136/bjo.2005.066431 PubMedCrossRef

23.

Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, Oshima Y, Kusaka S, Tano Y (2007) Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 91:161–165. doi:10.1136/bjo.2006.099887 PubMedCrossRef

24.

Tewari A, Dhalla MS, Apte RS (2006) Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 26:1093–1094. doi:10.1097/01.iae.0000254896.78766.74 PubMedCrossRef

25.

Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS (2007) Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91:157–160. doi:10.1136/bjo.2006.096776 PubMedCrossRef

26.

Steinbrook R (2006) The price of sight–ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 355:1409–1412. doi:10.1056/NEJMp068185 PubMedCrossRef

27.

Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179–2182. doi:10.1016/j.ophtha.2007.09.012 PubMedCrossRef

28.

Rosenfeld PJ (2007) Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. Br J Ophthalmol 91:128–130. doi:10.1136/bjo.2006.101337 PubMedCrossRef

29.

Holladay JT (1997) Proper method for calculating average visual acuity. J Refract Surg 13:388–391PubMed

30.

Ohno-Matsui K, Yoshida T, Uetama T, Mochizuki M, Morita I (2003) Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. Biochem Biophys Res Commun 303:962–967. doi:10.1016/S0006-291X(03)00446-7 PubMedCrossRef

31.

Ohno-Matsui K, Morita I, Tombran-Tink J, Mrazek D, Onodera M, Uetama T, Hayano M, Murota SI, Mochizuki M (2001) Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 189:323–333. doi:10.1002/jcp.10026 PubMedCrossRef

32.

Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS (2006) Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141:456–462. doi:10.1016/j.ajo.2005.10.012 PubMedCrossRef

33.

Kourlas H, Abrams P (2007) Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 29:1850–1861. doi:10.1016/j.clinthera.2007.09.008 PubMedCrossRef

34.

Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of Ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 145:239–248. doi:10.1016/j.ajo.2007.10.004 PubMedCrossRef

35.

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444. doi:10.1056/NEJMoa062655 PubMedCrossRef

36.

Nagpal M, Nagpal K, Nagpal PN (2007) A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). Indian J Ophthalmol 55:437–439PubMedCrossRef

37.

Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27:536–544. doi:10.1177/019262339902700507 PubMedCrossRef

38.

Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA (2007) Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 27:1260–1266PubMed

39.

Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859–870. doi:10.1097/01.iae.0000242842.14624.e7 PubMedCrossRef

40.

Olsen TW (2007) Treatment of exudative age-related macular degeneration: many factors to consider. Am J Ophthalmol 144:281–283. doi:10.1016/j.ajo.2007.05.005 PubMedCrossRef

41.

Sayanagi K, Ikuno Y, Soga K, Wakabayashi T, Tano Y (2008) Marginal crack after intravitreal bevacizumab for myopic choroidal neovascularization. Acta Ophthalmol (Copenh) 85:50–54

Title: Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization
Authors: Lazaros Konstantinidis
Irmela Mantel
Jean-Antoine C. Pournaras
Leonidas Zografos
Aude Ambresin
Publication date: 01-03-2009
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 3/2009
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-008-0995-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2009

Agreement between optical coherence tomography and digital stereophotography in vertical cup-to-disc ratio measurement

Nasal and independent polypoidal lesions in polypoidal choroidal vasculopathy

The effect of glycaemic control on the quantitative characteristics of retinopathy lesions in patients with type 2 diabetes mellitus: 10-year follow-up study

Evaluation of macular abnormalities in Stargardt’s disease using optical coherence tomography and scanning laser ophthalmoscope microperimetry

Preservation of photoreceptors in dystrophic RCS rats following allo- and xenotransplantation of IPE cells

Choroidal expansion during the water drinking test